

PRESENTED BY:



SPONSORED BY:



CONTINUING MEDICAL EDUCATION

## Pediatric Hematology/Oncology Tumor Board - 6/8/2023 – 55650-53867

Date: June 8, 2023

Time: 12:00 PM-1:00 PM

UH Cleveland Medical Center

*Duncan Stearns, MD; Rachel Egler, MD  
Case Western Reserve School of Medicine, Rainbow Babies and Children's Hospital*

### Educational Objectives

At the conclusion of this activity, the participant should be better able to:

- 1 Identify and apply the principles of quality and safety to their practice
- 2 Review appropriate therapeutic modalities
- 3 Discuss chemotherapy response
- 4 Evaluate survival and prognostic factors

### Accreditation and Credit Designation Statements

Case Western Reserve University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Case Western Reserve University School of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Disclosures:

All relevant financial relationships have been mitigated. This activity's planners and speaker(s) have made the following disclosures:

| Name of individual           | Individual's role in activity   | Name of Ineligible Company(s) / Nature of Relationship(s)   |
|------------------------------|---------------------------------|---|
| Duncan Stearns, MD           | Co-Director, Faculty            | Advisor-AstraZeneca (Relationship has ended) - 07/05/2022   |
| Rachel Egler, MD             | Course Director, Faculty        | Nothing to disclose - 06/10/2022  |
| Melissa Makii, PharmD        | Other Planning Committee Member | Paid consultant-Lexicomp Paid consultant-Takeda Pharmaceuticals, Inc. - 05/11/2023                                      |
| Kristen Nagle, CNP, MSN      | Other Planning Committee Member | Nothing to disclose - 06/30/2022  |
| Breanne Roche, DNP, RN, CPNP | Other Planning Committee Member | Paid consultant-BTG Specialty Pharmaceuticals Advisor-AstraZeneca (Relationship has ended) Advisor-Alexion - 06/30/2022 |